Keybanc Maintains Overweight on Steris, Lowers Price Target to $269

Benzinga Newsdesk www.benzinga.com Negative 89.3%

Neg 89.3% Neu 0% Pos 0%

Keybanc analyst Brett Fishbin maintains Steris (NYSE:STE) with a Overweight and lowers the price target from $291 to $269.